AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03621228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindfulGarden
Description: MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
Study NCT00294164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
Study NCT00294164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
Study NCT00294164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
Study NCT02534831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue manual therapy protocol
Description: The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
Study NCT00581074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet (grapefruit or grapefruit juice)
Description: weight loss diet
Study NCT03763448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar Fat Pad resection
Description: In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
Study NCT04337463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008
Description: Tablet
Study NCT04337463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: IV infusion
Study NCT04620005 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Survey
Study NCT04087005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hominis placental pharmacopuncture
Description: Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
Study NCT00581074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet (grapefruit or grapefruit juice)
Description: weight loss diet
Study NCT04087005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hominis placental pharmacopuncture
Description: Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
Study NCT01128699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival Avastin
Description: Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Study NCT01128699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Valve implant
Description: 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Study NCT02349100 — intervention group
Intervention type: DEVICE
Intervention: Nellix Endoprosthesis
Description: Implantation of Nellix
Study NCT03714139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day.
Study NCT03714139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non implant loading
Description: Control implants will receive a healing screw and will remain unloaded
Study NCT04114227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)
Description: Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
Study NCT04114227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy (Treatment as Usual Control)
Description: Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
Study NCT03588494 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy (CCRT)
Description: Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.
Study NCT03588494 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy (CCRT)
Description: Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.
Study NCT03588494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar for one cycle
Description: Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
Study NCT03588494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar for two cycles
Description: Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
Study NCT01138995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ness L300
Description: The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
Study NCT01138995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle-foot orthosis
Description: The Control Group will walk with a usual ankle-foot orthosis (AFO).
Study NCT00923481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: 200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
Study NCT01502228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150-Water
Description: Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
Study NCT01502228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 62Cu-ethylglyoxal bis
Description: Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
Study NCT01502228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: PET Scan
Study NCT01502228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT00719355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking with poles
Description: Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
Study NCT03500302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab sq once a month for a total of two doses
Study NCT03420456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Study NCT02354040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Rx
Description: For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
Study NCT03274791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of induced sputum
Description: Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa.
Study NCT03274791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function test
Description: All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis.
Study NCT03274791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked Immunosorbent Assay
Description: IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α.
Study NCT03351426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
Study NCT03351426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
Study NCT04669275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counselıng
Description: Telephone counseling
Study NCT03346109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: medial group retropharyngeal node（MRLN） sparing
Description: Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
Study NCT02219477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet; paritaprevir co-formulated with ritonavir and ombitasvir
Study NCT02219477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: tablet
Study NCT02219477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study NCT02630576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Description: Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
Study NCT00607321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Bifurcation Stent System
Description: Percutaneous Coronary Stenting
Study NCT03415646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: erector spinae plane block with double level injection will be administered before the surgery
Study NCT03415646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study NCT03415646 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study NCT02623569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Not Provided
Study NCT02623569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Not Provided
Study NCT03490253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIAMANTE Adaptive
Description: In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
Study NCT03490253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIAMANTE Static
Description: The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
Study NCT04820738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training exercises
Description: Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking
Study NCT04820738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Sensorimotor training exercises
Description: Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
Study NCT03253380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients
Description: Early rehabilitation of MV patients in the respiratory ICU
Study NCT03355872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: Biosimilar of Rituximab
Study NCT03355872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLX01
Description: Biosimilar of Rituximab
Study NCT04140942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
Study NCT04140942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT04140942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT00951587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ (Capsule Endoscopy)
Description: Medical Device
Study NCT02812823 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-resolution anorectal manometry
Description: Recording of conventional manometric parameters after insertion of the catheters.
Study NCT00719355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
Study NCT02726724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 observers
Study NCT03077074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low carbohydrate consumption
Description: consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
Study NCT02535858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and respiratory rate and VE
Description: To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
Study NCT02535858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and respiratory rate and video
Description: Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
Study NCT00656942 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Sensory Testing (QST)
Description: QST consists of a series of heat and cold stimulation tests.
Study NCT01728675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform two isokinetic eccentric exercise bouts
Study NCT03603626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Preemptive pregabalin 150 mg administered 1 hour before surgery
Study NCT03603626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo administered 1 hour before surgery
Study NCT00038025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycoformycin (DCF)
Description: Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
Study NCT03021681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: autologous bronchial basal cell transplantation
Description: the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
Study NCT02851017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
Study NCT04428034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Skills Together
Description: Information provided in arm/group description.
Study NCT03682107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andes virus DNA vaccine
Description: A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.